ABSTRACT:
This article summarizes the arguments and counterarguments in the framework of a scientific discussion on aging information on an example of the pharmaceutical industry. The main purpose of the study is to analyze the rate of becoing obsolete of certain types of pharmaceutical information and determine the length of stages of its life cycle. The urgency of solving this scientific problem is that the processes of working with the information, its search, processing, updating, usage and storage require significant labor and material resources, therefore, the definition of the degree of importance of pharmaceutical information and the facilitation of a decision on the need for actualization or further storage of that or other information is one of the areas of scientific research. The study of the issue of aging information in the article is carried out in the following logical sequence: the pharmaceutical information is structured according to the degree of aging, The lifecycle of hardware that participates in work with information is considered; the level of electronic sources of pharmaceutical information is analyzed, the degree of updating and the frequency of the new information on drugs emergence and the frequency of changes to a number of basic regulatory acts that are used to regulate the pharmaceutical industry are reviewed. The methodical tools of the study were methods of analysis and synthesis, concretization and system analysis, the period of research covers the last 30 years. The object of research is the pharmaceutical industry, since on one hand it has a tempting rate of information aging and, on the other hand it has great social significance. The article presents the results of empirical analysis of information aging, which showed that the life cycle of information lasts for a certain time and is limited to two events – the approval and the expiry of the validity. The study empirically confirms and theoretically proves that the pharmaceutical information has its own life cycle, and some of its phases significantly affect the level of aging information. The results of the research can be useful for pharmaceutical companies as well as for specialists, because the availability of relevant information makes it possible to reduce the risks to the health and life of patients associated with the possibility of errors.